Hims & Hers Health, Inc. $HIMS Shares Purchased by MAI Capital Management

by · The Cerbat Gem

MAI Capital Management raised its holdings in Hims & Hers Health, Inc. (NYSE:HIMS – Free Report) by 1,994.5% in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 6,514 shares of the company’s stock after acquiring an additional 6,203 shares during the period. MAI Capital Management’s holdings in Hims & Hers Health were worth $325,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the business. Smartleaf Asset Management LLC grew its position in shares of Hims & Hers Health by 15.7% in the first quarter. Smartleaf Asset Management LLC now owns 1,672 shares of the company’s stock valued at $49,000 after purchasing an additional 227 shares during the period. Bessemer Group Inc. lifted its position in Hims & Hers Health by 105.8% during the second quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock worth $30,000 after buying an additional 312 shares during the period. True Vision MN LLC boosted its stake in Hims & Hers Health by 3.6% in the 2nd quarter. True Vision MN LLC now owns 9,376 shares of the company’s stock worth $467,000 after buying an additional 328 shares during the last quarter. WealthPlan Investment Management LLC boosted its stake in Hims & Hers Health by 2.6% in the 2nd quarter. WealthPlan Investment Management LLC now owns 16,404 shares of the company’s stock worth $818,000 after buying an additional 410 shares during the last quarter. Finally, Securian Asset Management Inc. grew its holdings in Hims & Hers Health by 2.8% in the 2nd quarter. Securian Asset Management Inc. now owns 14,931 shares of the company’s stock valued at $744,000 after buying an additional 411 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, insider Michael Chi sold 900 shares of the company’s stock in a transaction that occurred on Friday, October 10th. The stock was sold at an average price of $58.25, for a total value of $52,425.00. Following the completion of the transaction, the insider owned 291,439 shares in the company, valued at $16,976,321.75. This represents a 0.31% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Oluyemi Okupe sold 23,187 shares of the stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $36.81, for a total transaction of $853,513.47. Following the completion of the sale, the chief financial officer directly owned 70,232 shares of the company’s stock, valued at $2,585,239.92. This trade represents a 24.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 616,431 shares of company stock valued at $32,924,482 over the last quarter. Company insiders own 13.71% of the company’s stock.

Hims & Hers Health Stock Performance

Shares of HIMS stock opened at $38.54 on Thursday. The company has a current ratio of 1.88, a quick ratio of 1.64 and a debt-to-equity ratio of 1.67. The company has a market cap of $8.77 billion, a PE ratio of 71.36, a P/E/G ratio of 7.38 and a beta of 2.20. The company’s fifty day simple moving average is $48.27 and its 200-day simple moving average is $50.85. Hims & Hers Health, Inc. has a 52 week low of $23.97 and a 52 week high of $72.98.

Hims & Hers Health (NYSE:HIMS – Get Free Report) last announced its quarterly earnings results on Monday, November 3rd. The company reported $0.06 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). Hims & Hers Health had a return on equity of 24.67% and a net margin of 6.05%.The business had revenue of $598.98 million for the quarter, compared to analysts’ expectations of $578.99 million. During the same period last year, the company posted $0.32 earnings per share. The firm’s revenue for the quarter was up 49.2% on a year-over-year basis. Hims & Hers Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hims & Hers Health declared that its board has approved a share repurchase program on Monday, November 17th that permits the company to buyback $250.00 million in outstanding shares. This buyback authorization permits the company to repurchase up to 3% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s management believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on HIMS. UBS Group set a $32.00 price objective on shares of Hims & Hers Health in a report on Tuesday, November 4th. Needham & Company LLC reaffirmed a “hold” rating on shares of Hims & Hers Health in a research report on Tuesday, August 5th. KeyCorp initiated coverage on shares of Hims & Hers Health in a research note on Tuesday, October 21st. They set a “sector weight” rating on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of Hims & Hers Health in a report on Monday. Finally, Wall Street Zen cut shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Two research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Reduce” and an average price target of $45.27.

Check Out Our Latest Stock Analysis on HIMS

Hims & Hers Health Profile

(Free Report)

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Read More